0

Close
 
Upcoming Allied Market Research
2023
Hemorrhagic Stroke Drugs Market

Hemorrhagic Stroke Drugs Market

by Type (Antihypertensive, Anticoagulant, Diuretics, Anticonvulsants, others) and by End User (Hospital, Ambulatory Surgical Center, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A12328
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Hemorrhagic Stroke Drugs Market

Request Now !

Hemorrhagic stroke, commonly known as cerebral hemorrhage, is a condition caused by the rupturing of cerebral blood vessels. Hemorrhagic stroke is mainly of two types - intracerebral hemorrhage and subarachnoid hemorrhage. Intracerebral hemorrhage happens when a deteriorated blood vessel inside the brain ruptures and leaks blood into neighboring brain tissues.

Aneurysms and arteriovenous malformations are the damaged blood vessels that usually cause hemorrhagic stroke. Overuse of antihypertensive drugs is often held responsible for hemorrhagic stroke. In the brain, bleeding occurs due to brain tumor, accidents, stroke, or high blood pressure, or other health conditions. Of all the stroke cases, 13% strokes are hemorrhagic strokes. Still, it is accountable for about 40% of all stroke casualties and signifies the extremely severe subtypes of stroke.

COVID-19 Impact Analysis

COVID-19 has left tremendous pressure on healthcare services. With the anticipated pathophysiological mechanism of neurologic injury by COVID-19, it was expected that the frequency of stroke and hospital admissions were expected to increase. But neurologists in recent months from different parts of the world have notified a fair drop in the volume of acute 0stroke patients visiting emergency care.

A study done by the National Institute of Neurosciences and Hospital (NINS&H) revealed more than 50% decrease in acute stroke admission throughout the COVID-19 pandemic. Whether the reduction is related to the overall restriction on public movement by the government or is it the concern of getting infected by COVID-19 from hospitalization remains unidentified.

Top Impacting Factors

  • High chances of increase in the occurrences of stroke because of the lifestyle changes and growing problems of chronic diseases, is expected to boost the hemorrhagic stroke drugs market.
  • The shorter onset of action of hemorrhagic stroke drugs is likely to drive the market.
  • The natural and pathological changes that arise with the aging population make the central nervous system and cardiovascular system more prone to strokes, which are anticipated to help the hemorrhagic stroke drugs market thrive.
  • High cost of the treatment and potential side effects from medications are expected to restrict the market growth during the forecast period.
  • Patent expiry and entry of generics into the market can slow down the demand for branded drugs, thereby negatively affecting the market growth.
  • Advancement of novel therapies for hemorrhagic stroke medication is one of the substantial trends of the hemorrhagic stroke drug market. Numerous possible new treatment approaches have been developed or are under development to offer better therapies to the patients which are expected to boost the market growth.
  • Factors such as the rising incidence in the aging population and the advanced diagnostic modalities for hemorrhagic stroke resurgence are anticipated to provide substantial growth opportunities to hemorrhagic stroke treatment companies.

Market Trends

New Product Launches to Flourish the Market

In November, 2020, AstraZeneca’s Brilinta (ticagrelor) was approved in the U.S. to reduce the risk of stroke, a leading cause of disability and death worldwide.

In February 2020, Abbott Laboratories got the approval for Amplatzer Amulet left atrial appendage to occlude by the U.S. FDA for the people suffering from stroke. This approach assisted the company in expanding its stroke management product portfolio.

Surge in Usage in Hemorrhagic Stroke Treatment

The hemorrhagic stroke market has witnessed several novel therapies that are designed specifically to enhance stroke outcomes. In addition, rise in adoption of hemorrhagic stroke treatment can be credited to the current high unmet medical needs and entry of highly priced therapies in the market. Key players are aiming at advancement of new drugs and stem cell therapies with improved efficacy.

Key Benefits of the Report

  • This study presents the analytical depiction of the hemorrhagic stroke drugs market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the hemorrhagic stroke drugs market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers in the market.
  • The report provides a detailed analysis of the hemorrhagic stroke drugs market based on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Hemorrhagic Stroke Drugs Market Report

  • Which are the leading players active in the hemorrhagic stroke drugs market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What future projections are expected to help in taking further strategic steps?
  • What is "hemorrhagic stroke drugs“?
  • What is "hemorrhagic stroke drugs" market prediction in the future?
  • Who are the leading global players in the "hemorrhagic  stroke drugs" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "hemorrhagic stroke drugs" market report?

 Hemorrhagic Stroke Drugs Market Report Highlights

Aspects Details
By Type
  • Antihypertensive
  • Anticoagulant
  • Diuretics
  • Anticonvulsants
  • others
By End User
  • Hospital
  • Ambulatory Surgical Center
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players AstraZenica, Amneal Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Zydus Cadila, Bristol-Myers Squibb Company, Daiichi Sankyo Company, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, Novartis AG, Johnson and Johnson Services, Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: HEMORRHAGIC STROKE DRUGS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Antihypertensive

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Anticoagulant

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Diuretics

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Anticonvulsants

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: HEMORRHAGIC STROKE DRUGS MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospital

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Ambulatory Surgical Center

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: HEMORRHAGIC STROKE DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Hemorrhagic Stroke Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Hemorrhagic Stroke Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Hemorrhagic Stroke Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Hemorrhagic Stroke Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Hemorrhagic Stroke Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Hemorrhagic Stroke Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Hemorrhagic Stroke Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Hemorrhagic Stroke Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Hemorrhagic Stroke Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Hemorrhagic Stroke Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Hemorrhagic Stroke Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Hemorrhagic Stroke Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Hemorrhagic Stroke Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Hemorrhagic Stroke Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Hemorrhagic Stroke Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Hemorrhagic Stroke Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Hemorrhagic Stroke Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Hemorrhagic Stroke Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Hemorrhagic Stroke Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Hemorrhagic Stroke Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Hemorrhagic Stroke Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Hemorrhagic Stroke Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Hemorrhagic Stroke Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Hemorrhagic Stroke Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Hemorrhagic Stroke Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Novartis AG

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Daiichi Sankyo Company

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Zydus Cadila

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. F. Hoffmann-La Roche Ltd.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Boehringer Ingelheim International GmbH

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Amneal Pharmaceuticals LLC

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Teva Pharmaceutical Industries Ltd.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. AstraZenica

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Bristol-Myers Squibb Company

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Johnson And Johnson Services, Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET FOR ANTIHYPERTENSIVE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET FOR ANTICOAGULANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET FOR DIURETICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET FOR ANTICONVULSANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET FOR HOSPITAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET FOR AMBULATORY SURGICAL CENTER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA HEMORRHAGIC STROKE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 15. U.S. HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 16. U.S. HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. CANADA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. CANADA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 20. MEXICO HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE HEMORRHAGIC STROKE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. GERMANY HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. ITALY HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 29. ITALY HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. UK HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. UK HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. RUSSIA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. RUSSIA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. REST OF EUROPE HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC HEMORRHAGIC STROKE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. CHINA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 42. CHINA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. JAPAN HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. JAPAN HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. INDIA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. INDIA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 48. SOUTH KOREA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. AUSTRALIA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. AUSTRALIA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. THAILAND HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. THAILAND HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. MALAYSIA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. MALAYSIA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. INDONESIA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. INDONESIA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA HEMORRHAGIC STROKE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. BRAZIL HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. BRAZIL HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH AFRICA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH AFRICA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. SAUDI ARABIA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 67. SAUDI ARABIA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. UAE HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. UAE HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. ARGENTINA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. ARGENTINA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. REST OF LAMEA HEMORRHAGIC STROKE DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 73. REST OF LAMEA HEMORRHAGIC STROKE DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 75. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 76. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 77. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 78. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. DAIICHI SANKYO COMPANY: KEY EXECUTIVES
  • TABLE 80. DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT
  • TABLE 81. DAIICHI SANKYO COMPANY: OPERATING SEGMENTS
  • TABLE 82. DAIICHI SANKYO COMPANY: PRODUCT PORTFOLIO
  • TABLE 83. DAIICHI SANKYO COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. ZYDUS CADILA: KEY EXECUTIVES
  • TABLE 85. ZYDUS CADILA: COMPANY SNAPSHOT
  • TABLE 86. ZYDUS CADILA: OPERATING SEGMENTS
  • TABLE 87. ZYDUS CADILA: PRODUCT PORTFOLIO
  • TABLE 88. ZYDUS CADILA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 90. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 91. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 92. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 93. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 95. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 96. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OPERATING SEGMENTS
  • TABLE 97. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 98. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 100. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 101. AMNEAL PHARMACEUTICALS LLC: OPERATING SEGMENTS
  • TABLE 102. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 103. AMNEAL PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 106. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 107. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 108. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. ASTRAZENICA: KEY EXECUTIVES
  • TABLE 110. ASTRAZENICA: COMPANY SNAPSHOT
  • TABLE 111. ASTRAZENICA: OPERATING SEGMENTS
  • TABLE 112. ASTRAZENICA: PRODUCT PORTFOLIO
  • TABLE 113. ASTRAZENICA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 115. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 116. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 117. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 118. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. JOHNSON AND JOHNSON SERVICES, INC.: KEY EXECUTIVES
  • TABLE 120. JOHNSON AND JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
  • TABLE 121. JOHNSON AND JOHNSON SERVICES, INC.: OPERATING SEGMENTS
  • TABLE 122. JOHNSON AND JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
  • TABLE 123. JOHNSON AND JOHNSON SERVICES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HEMORRHAGIC STROKE DRUGS MARKET
  • FIGURE 3. SEGMENTATION HEMORRHAGIC STROKE DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HEMORRHAGIC STROKE DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHEMORRHAGIC STROKE DRUGS MARKET
  • FIGURE 11. HEMORRHAGIC STROKE DRUGS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. HEMORRHAGIC STROKE DRUGS MARKET FOR ANTIHYPERTENSIVE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. HEMORRHAGIC STROKE DRUGS MARKET FOR ANTICOAGULANT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. HEMORRHAGIC STROKE DRUGS MARKET FOR DIURETICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. HEMORRHAGIC STROKE DRUGS MARKET FOR ANTICONVULSANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. HEMORRHAGIC STROKE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. HEMORRHAGIC STROKE DRUGS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 18. HEMORRHAGIC STROKE DRUGS MARKET FOR HOSPITAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. HEMORRHAGIC STROKE DRUGS MARKET FOR AMBULATORY SURGICAL CENTER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. HEMORRHAGIC STROKE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: HEMORRHAGIC STROKE DRUGS MARKET
  • FIGURE 27. Top player positioning, 2022
  • FIGURE 28. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 29. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 30. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 31. DAIICHI SANKYO COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. DAIICHI SANKYO COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. DAIICHI SANKYO COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. ZYDUS CADILA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. ZYDUS CADILA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. ZYDUS CADILA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. AMNEAL PHARMACEUTICALS LLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. ASTRAZENICA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. ASTRAZENICA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. ASTRAZENICA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. JOHNSON AND JOHNSON SERVICES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Hemorrhagic Stroke Drugs Market

Start reading.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers